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Dominican Research Advances Anti-Malarial Drugs 
 
The researchers have generated drug-resistant mutations that visibly change the digestive 
organelle ofPlasmodium falciparum, the blood parasite that causes malaria. The mutation causes 
grossly enlarged food vacuoles in the malaria parasite. These changes were found to alter 
susceptibility to specific anti-malarial drugs, said Roland Cooper, associate professor of biology 
at Dominican. 
The ability to actually see the impact of drug resistance to the parasite will help scientists 
understand how micro-organisms can evolve to become drug resistant. Findings provide tools for 
understanding mechanisms of action of different classes of anti-malarial drugs, as well the cell 
biology of the parasite. 
“We are able to see visible changes in the parasite’s digestive organelle and can actually see the 
effects of the drug resistance mutations,” Cooper said. “Because these changes correlate with 
drug resistance, we can understand how the parasite deals with the physiology of becoming drug 
resistant.” 
CLICK HERE TO READ THE MARIN INDEPENDENT JOURNAL FRONT PAGE STORY 
ON DR. COOPER 
Malaria remains one of the world’s deadliest diseases. Each year, malaria causes up to 660 
million clinical cases and claims around one million lives, mostly children under the age of five 
and pregnant women of sub-Saharan Africa. The situation is largely attributed to the spread of 
multi-drug resistant Plasmodium falciparum. With no vaccine available, there is a dire need for 
low cost, effective, safe, and sustainable malaria treatments. 
Scientists involved with the multi-institution collaboration are focused on understanding how P. 
falciparumresponds to a diverse range of anti-malarial drugs by examining the molecular 
mechanism of drug action and resistance in the parasite. Specifically, the researchers are 
investigating the structure/function relationship of a drug-resistant protein, known as PfCRT (P. 
falciparum chloroquine resistance transporter). This protein occurs on the malaria parasite food 
vacuole membrane, so mutations in the protein sometimes lead to directly observable effects on 
parasite physiology. 
Cooper and the research collaborators recently presented the findings at the Annual Molecular 
Parasitology Meeting in Woods Hole, MA. 
Meanwhile, Cooper and two of his Dominican students will present their malaria research in 
November at the American Society of Tropical Medicine and Hygiene meeting in Washington, 
DC. 
Cooper and graduate student Stephanie Huezo and senior biology major Melissa Forbush will 
present two posters focused on Cooper’s ongoing research examining the effectiveness of two 
experimental malaria drugs in preclinical investigation. These studies are part of a long-standing 
collaboration with researchers at Portland State University and DesignMedix Inc., of Portland 
OR. 
Huezo is the lead author on the poster titled “Selection of Plasmodium falciparum Resistance to 
Antimalarial Acridones.” Forbush is lead author on the poster titled “Selection of Cytotoxic 
Resistance to a Reversed-Chloroquine Compound in Plasmodium falciparum.” 
Cooper and Huezo have spent the summers working on a clinical trial in Uganda focused on 
studying the effectiveness of the two drugs against parasites by examining blood extracted from 
patients at Tororo District Hospital in eastern Uganda. Findings show that the experimental anti-
malarial drugs, which due to the proprietary nature of the clinical trial cannot be named at this 
point, to be highly effective. 
Cooper joined Dominican’s faculty in 2011. His NIH-funded research is focused on the 
molecular mechanism of drug action and resistance in the human malaria parasite, Plasmodium 
falciparum. His projects are based both in the laboratory and Uganda. Dr. Cooper teaches 
Advanced Genetics, Medical Parasitology and Research Methodology. 






Media contact: Sarah Gardner, sarah.gardner@dominican.edu, 415-485-3239. 
 
October 17, 2014 
